hydroxychloroquine has been researched along with Idiopathic Inflammatory Myopathies in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study we investigated COVID-19 vaccination-related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs)." | 1.72 | COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies. ( Agarwal, V; Aggarwal, R; Cavagna, L; Chatterjee, T; Chinoy, H; Day, J; Distler, O; Gaur, PS; Gheita, T; Gil-Vila, A; Gonzalez, RA; Gracia-Ramos, AE; Gupta, L; Joshi, M; Kardes, S; Kim, M; Knitza, J; Kuwana, M; Lilleker, JB; Makol, A; Milchert, M; Nikiphorou, E; Nune, A; Parodis, I; Ravichandran, N; Saavedra, MA; Salim, B; Selva-O'Callaghan, A; Sen, P; Shinjo, SK; Tan, AL; Velikova, T; Ziade, N, 2022) |
| "A control group of 16 patients with idiopathic inflammatory myositis (IIM) on HCQ at time of biopsy but without evidence of CB was identified." | 1.46 | Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing. ( Blumbergs, P; Khoo, T; Koszyca, B; Lester, S; Limaye, V; Otto, S; Smith, C, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Gil-Vila, A | 1 |
| Ravichandran, N | 1 |
| Selva-O'Callaghan, A | 1 |
| Sen, P | 1 |
| Nune, A | 1 |
| Gaur, PS | 1 |
| Gonzalez, RA | 1 |
| Lilleker, JB | 1 |
| Joshi, M | 1 |
| Agarwal, V | 2 |
| Kardes, S | 1 |
| Kim, M | 1 |
| Day, J | 1 |
| Makol, A | 1 |
| Milchert, M | 1 |
| Gheita, T | 1 |
| Salim, B | 1 |
| Velikova, T | 1 |
| Gracia-Ramos, AE | 1 |
| Parodis, I | 1 |
| Nikiphorou, E | 1 |
| Tan, AL | 1 |
| Chatterjee, T | 1 |
| Cavagna, L | 1 |
| Saavedra, MA | 1 |
| Shinjo, SK | 1 |
| Ziade, N | 1 |
| Knitza, J | 1 |
| Kuwana, M | 1 |
| Distler, O | 1 |
| Chinoy, H | 1 |
| Aggarwal, R | 1 |
| Gupta, L | 1 |
| Uslu, S | 1 |
| Bozkirli, DE | 1 |
| Kozanoglu, I | 1 |
| Bozkirli, E | 1 |
| Yucel, E | 1 |
| Khoo, T | 1 |
| Otto, S | 1 |
| Smith, C | 1 |
| Koszyca, B | 1 |
| Lester, S | 1 |
| Blumbergs, P | 1 |
| Limaye, V | 1 |
| LOUYOT, P | 1 |
| GAUCHER, A | 1 |
| JEANBLANC, J | 1 |
| MONTET, Y | 1 |
| Muirden, KD | 1 |
| Ponge, T | 1 |
| Mussini, JM | 1 |
| Ponge, A | 1 |
| Forgeau, Y | 1 |
| Barrier, J | 1 |
| Cottin, S | 1 |
| Grolleau, JY | 1 |
1 review available for hydroxychloroquine and Idiopathic Inflammatory Myopathies
| Article | Year |
|---|---|
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
1 trial available for hydroxychloroquine and Idiopathic Inflammatory Myopathies
| Article | Year |
|---|---|
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
6 other studies available for hydroxychloroquine and Idiopathic Inflammatory Myopathies
| Article | Year |
|---|---|
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies.
Topics: Adult; Animals; Autoimmune Diseases; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Exanthema; Female; | 2022 |
Myositis due to COVID-19.
Topics: Adult; Amides; Antiviral Agents; C-Reactive Protein; COVID-19; COVID-19 Nucleic Acid Testing; Creati | 2021 |
Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis.
Topics: Aged; Autoantibodies; Azathioprine; Combined Modality Therapy; Creatine Kinase; Cyclophosphamide; Em | 2013 |
Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing.
Topics: Antirheumatic Agents; Databases, Factual; Humans; Hydroxychloroquine; Muscle Weakness; Muscle, Skele | 2017 |
[EVALUATION OF LONG-TERM THERAPY WITH CHLOROQUINE AND HYDROXYCHLOROQUINE IN RHEUMATOLOGY].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Drug Therapy; Humans; Hydrarthrosis; Hydroxychloroqui | 1964 |
[Primary Gougerot-Sjögren syndrome with necrotizing polymyositis: favorable effect of hydroxychloroquine].
Topics: Female; Humans; Hydroxychloroquine; Middle Aged; Myositis; Sjogren's Syndrome | 1987 |